Adcytherix SAS has successfully raised €105 million in a Series A funding round to advance its innovative antibody-drug conjugate pipeline, with a strategic focus on novel payloads.

Target Information

Adcytherix SAS is a biopharmaceutical firm based in Marseille, France, specializing in the design and development of novel and proprietary antibody-drug conjugates (ADCs). With a commitment to advancing targeted cancer treatments, Adcytherix aims to address the significant unmet needs in oncology through innovative approaches utilizing new payload classes. The company is poised to solidify its position in a competitive market and is determined to bring effective therapies to patients.

Recently, Adcytherix secured €105 million (approximately US$122 million) in a Series A financing round, making it one of the most promising ADC developers in Europe. The funding will primarily support the advancement of its lead candidate, ADCX-020, into clinical trials, with plans for the first investigational new drug (IND) and clinical trial application (CTA) filings by the end of 2025.

Industry Overview

The global market for antibody-drug conjugates has been experiencing rapid growth, fueled by increasing investments and advancements in therapeutic technologies. Europe, in particular, has become a hub for biopharmaceutical innovation, with a robust ecosystem of research